Guinea-Bissau has announced the suspension of a hepatitis B vaccine study on newborns, which was backed by the Trump administration, pending a comprehensive ethical review. The West African nation's health minister confirmed the decision on Thursday, highlighting procedural concerns that have raised significant ethical questions about the research design.
Ethical Oversight Concerns Prompt Immediate Suspension
Health Minister Quinhi Nantot stated during a news conference held by the Africa Centers for Disease Control and Prevention that a six-person ethics committee failed to convene to review the study during the initial confirmation process. This oversight has led to the temporary halt of the randomised controlled trial, which involves administering the hepatitis B vaccine to some infants at birth while withholding it from others.
Study Design and Controversial Methodology
The study, designed to track children for death, illness, and long-term developmental outcomes, has faced criticism from experts who argue that withholding proven vaccines from newborns at significant risk of infection is unethical. The research plan, which involves following 14,000 newborns over five years, with most children monitored for less than two years for side effects and the first 500 followed for five years for behaviour and brain development issues, has sparked alarm within the public health community.
Africa CDC Director-General Jean Kaseya expressed full support for the ethical review, emphasising the agency's commitment to African interests rather than individual agendas. "We are led by the interests of our people in Africa," Kaseya said. "We are not led by the small interests of individual people."
US Government and Contract Details
Despite the suspension, US health officials maintained on Wednesday that the study is still set to proceed. Andrew Nixon, spokesman for the US Department of Health and Human Services, stated, "The study is proceeding as planned, and we continue to work with our partners to finalise the study's protocols."
The Trump administration awarded a $1.6 million, no-bid contract to the University of Southern Denmark for this research in Guinea-Bissau, an impoverished nation where hepatitis B infection is common. The contract was granted to scientists whose work has been cited by anti-vaccine activists and questioned by leading public health experts, adding another layer of controversy to the study.
Research Team and Political Connections
The US Centers for Disease Control and Prevention awarded the grant to a research team at the University of Southern Denmark that has been praised by US Health Secretary Robert F. Kennedy Jr. One of the team's leaders, Christine Stabell Benn, serves as a consultant for a Kennedy-appointed committee that recently voted to stop recommending a dose of hepatitis B vaccine for all American newborns.
This connection has further intensified scrutiny, as widespread medical consensus holds that the hepatitis B vaccine effectively protects newborns, making the decision to withhold it from some participants ethically problematic. The study's initial design did not involve a placebo, though Nixon did not release additional details about the current version of the study design.
The suspension underscores ongoing tensions between global health initiatives and ethical standards, particularly in vulnerable populations. As the review progresses, stakeholders await further developments that could reshape the future of vaccine research in low-income countries.
